A potential new prodrug for the treatment of cystinosis:Design, synthesis and in-vitro evaluation

Bridgeen McCaughan, Graeme Kay, Rachel M Knott, Donald Cairns

    Research output: Contribution to journalArticle

    16 Citations (Scopus)

    Abstract

    Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in thecells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasanttasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attemptto improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathiccystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts.This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteaminebitartrate.
    Original languageEnglish
    Pages (from-to)1716-1719
    JournalBioorganic & Medicinal Chemistry Letters
    Volume18
    DOIs
    Publication statusPublished - 12 Jan 2008

    Fingerprint Dive into the research topics of 'A potential new prodrug for the treatment of cystinosis:Design, synthesis and in-vitro evaluation'. Together they form a unique fingerprint.

  • Cite this